SGCM
FOLD

Sand Grove Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Sand Grove Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,647,030
Closed -$23.5M – 24
2025
Q4 		$23.5M Buy
+1,647,030
New +$16.2M 7.95% 8

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sand Grove Capital Management's FOLD Position: Q1 2026 in Review

Sand Grove Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 1,647,030 shares — an estimated $23.5M sold.

Sand Grove Capital Management first reported a position in FOLD in Q4 2025 and held it in 1 quarter. The position peaked at $23.5M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Sand Grove Capital Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sand Grove Capital Management sold 1,647,030 Amicus Therapeutics shares in Q1 2026, an estimated $23.5M.
  • Sand Grove Capital Management first reported a position in Amicus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Sand Grove Capital Management's Amicus Therapeutics position peaked at $23.5M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Sand Grove Capital Management's 13F filing for Q1 2026, filed 15 May 2026.